The Effect of Intra-Articular Injection of RegenoGel-OSP™(Self-Plasma) to Treat Pain Following Arthroscopic Surgery

NCT ID: NCT03059706

Last Updated: 2017-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-23

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ to treat pain and the safety and efficacy on subject's activity and quality of life following arthroscopic surgery due to degenerative or traumatic meniscal tear. adult subjects will be randomized and sequentially assigned to RegenoGel-OSP™ or placebo treatment on a 1:1 basis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meniscal Tear

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RegenoGel-OSP™

Group Type EXPERIMENTAL

RegenoGel-OSP™

Intervention Type DEVICE

intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery

Placebo

Group Type PLACEBO_COMPARATOR

saline

Intervention Type OTHER

intra-articular injection of saline after arthroscopic surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RegenoGel-OSP™

intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery

Intervention Type DEVICE

saline

intra-articular injection of saline after arthroscopic surgery

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has signed and dated the informed consent form.
* Subject is a male or female over the age of 45.
* Patients scheduled for knee arthroscopic surgery due to degenerative or traumatic meniscal tear.

Exclusion Criteria

* Subject had any intra-articular injections to the intended study knee within 3 months prior to Screening.
* Subject is unable to stop chronic administration of pain medications (including paracetamol), from the day before each study visit through completion of the study visit.
* Subject has a history of Psoriatic Arthritis, Rheumatoid Arthritis,or any other inflammatory condition associated with arthritis.
* Subject has a superficial wound in the area of the intended study knee.
* Subject is scheduled for knee ligaments reconstructive surgery.
* Subject has fever signs or symptoms of systemic infection or infection of the intended study knee.
* Subject has known sensitivity to any of the treatment components, egg, rubber or latex.
* Subject has a history of anaphylactic shock or other severe systemic response or other adverse event to human blood products.
* Subject has a clinically significant abnormal finding (e.g., laboratory result or ECG).
* Subject has known Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS), Hepatitis B or C viral infections, or acute or chronic liver disease.
* Subject has ever had cellulitis of the lower extremities, a superficial or deep vein thrombosis, or a family history of a clotting disorders.
* Subject receives any investigational device or product within 30 days of Visit l.
* Subject is receiving an oral or injected anticoagulant.
* Subject ever abused drugs or alcohol (self-reported).
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ProCore Ltd.

INDUSTRY

Sponsor Role collaborator

Kaplan Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Philip Rosinsky

Resident in Orthopedic Surgery Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaplan Medical Center

Rehovot, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philip Rosinsky

Role: CONTACT

0508990006

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Philip Rosinsky, MD

Role: primary

0508990006

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PROC-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ALGRX 4975 After Total Knee Replacement
NCT00132392 COMPLETED PHASE2
Post-operative Efficacy and Safety Study
NCT00904085 COMPLETED PHASE3